Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax/Nycomed merger would create contrast media, generic drug firm with $2.5 bil. in sales.

This article was originally published in The Gray Sheet

Executive Summary

IVAX IV BUSINESS TO BENEFIT FROM NYCOMED'S U.S. HOSPITAL TIES as a result of the proposed $6.5 bil. merger of the two firms, the companies say. The deal would enable Ivax' intravenous solutions and products business to "benefit substantially" from the "excellent U.S. hospital relationships" and "international hospital distribution channels" Hafslund Nycomed has established through its market-leading position in contrast imaging agents. Miami-based Ivax and Oslo, Norway-based Hafslund Nycomed announced Oct. 18 a definitive agreement to combine their health care products businesses.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004897

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel